Two recent clinical studies on Pomella® showed significant improvements in cardiovascular and metabolic health, respectively, with administration of 300 mg / Pomella® twice daily for 30-days as an adjunct therapy. In the first study, significant improvements were seen in biomedical parameters such as HDL, OX-LDL, serum homocysteine, hs-CRP, and others. The same researchers showed especially significant decreases in blood glucose and HbA1c compared to baseline in the second study.
Pomella® is a patented, clinically researched pomegranate extract developed in collaboration with a major research university located in California. It is produced by Verdure Sciences, the makers of Longvida®.
Pomella® is standardised to punicalagins (which are highly bioavailable) along with the natural spectrum of pomegranate fruit polyphenols. A 2014 study published in the Journal of Agricultural and Food Chemistry showed Pomella® ranked highest in antioxidant activity across a number of assays including ORAC, TEAC, FRAP and DPPH, compared to 26 other antioxidant ingredients. For more information, visit our dedicated Pomella® page.
Gee Lawson, Nutritional Division of LEHVOSS UK, is the exclusive distributor partner for Pomella® in Europe. Contact your sales manager for a quote and/or a sample.